Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| STAAR SURGIC | STAA | 10.98% |
| DTS INC | DTSI | 6.89% |
| ANIKA THERAP | ANIK | 6.04% |
| LUMOS NETWOR | LMOS | 5.70% |
| INSTEEL IND | IIIN | 5.28% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Better-than-expected manufacturing sector data out of China and Europe should help stocks sustain the positive momentum from Friday’s Europe-inspired gains, at least at the start of today’s trading action. But the gains may not have much staying power should domestic data, particularly the June Manufacturing ISM reading, turn out to be disappointing.
RELATED ARTICLESSpain’s spectacular victory over Italy in Sunday’s Euro Cup final may have established the country as the undisputed king of Soccer, but that is no help to the country’s fiscal woes. What will help the country instead will be positive follow-through from Friday’s Euro-zone announcements. Yields on Spanish (and Italian) government bonds are down again today, building on the new emerging trend from Friday.
We will have to wait and see whether this trend will remain in place over the coming days and weeks, but some optimism over the Friday announcement is definitely warranted.
Whether the Euro-zone crisis is the cause of the ongoing global economic slowdown or not, it is nevertheless a net drag on the growth outlook. Today’s PMI readings confirm the impact of the debt crisis on the region’s economy and its impact on China through the trade channel. China’s PMI reading from over the weekend, while better than expected, showed the sharp deceleration in the country’s export machine.
The U.S. economy has been showing a lot more resilience in the face of these headwinds, but the expectations for today’s June Manufacturing ISM report is to show a pullback from last month’s level. We have a number of other major economic reports on the docket this holiday-shortened week as well, but the focus will be on the labor market with the June non-farm payroll report coming out on Friday.
The expectation is for job gains of close to 100K in June, but we will have to wait until Friday to find out if even this lowered expectation can be met.
In corporate news, Bristol-Myers Squibb (BMY - Analyst Report) is acquiring diabetes drug maker Amylin Pharmaceutical (AMLN) for $5.3 billion in cash. In other deals, Ingram Micro (IM - Analyst Report) is acquiring the wireless equipment maker Brightpoint (CELL) for $622 million.
ISM Manufacturing Index Misses Expectations
Can the First Half's Big Winners Stay Strong?
Is Europe Fixed Already?
Get the full Analyst Report on IM - FREE
Get the full Analyst Report on BMY - FREE